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1. Introduction 
 
Myeloproliferative neoplasms (MPNs) are hematopoietic stem cell (HSC) disorders characterized by 
increased proliferation of one or more hematopoietic cell lineages with the highest incidence in the 
elderly population.2 Chronic myeloid leukemia (CML) is defined by the presence of the BCR-ABL1 
gene fusion transcript. Polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis 
(MF) are distinguished from CML by the absence of BCR-ABL1. More than 50 years ago William 
Damashek postulated that PV, ET and MF (i.e. BCR-ABL1 negative MPNs, henceforth abbreviated 
MPNs) originate from a common clonal ancestor since they share a common clinical phenotype.4 
BCR-ABL1 negative MPN patients are at increased risk for cardiovascular events, thromboembolic 
complications, bleedings, and infections which cause significant morbidity and mortality.5 In addition, 
MPNs can progress to acute myeloid leukemia (AML).  
In 2005, with the discovery of a recurrent unique somatic point mutation in Exon 14 of the Januskinase 
2 (JAK2) in BCR-ABL1 negative MPNs, a common clonal origin to PV, ET and MF was identified and 
confirmed the hypothesis postulated by Damashek earlier.1,6-10 The discovery of the JAK2 mutation 
revolutionized the field of MPNs and related disorders in basic and clinical research. In the last decade 
new sequencing technologies have uncovered a plethora of somatic mutation in these diseases, which 
contribute to the better understanding of their pathogenesis. In this endeavor the mutations in the ER 
resident chaperone Calreticulin (CALR) were first described two years ago in ET and MF patients with 
unmutated JAK2.1,10 Today, JAK inhibitors are available and Ruxolitinib, the first in class JAK inhibitor, 
has been approved by the food and drug administration for the treatment of advanced stage MPN.11,12  
 
The focus of my research is the investigation of mechanisms that contribute to the pathogenesis of 
MPNs. In the last years I have uncovered processes that contribute to the leukemic transformation of 
MPN and recently described how CALR mutations can affect the chaperone function of CALR. 13-15 
 
The leukemic transformation process in MPN  
MPNs can progress to AML, which is clinically indistinguishable from de novo AML (i.e. an AML that 
does not arise from an antecedent hematopoietic neoplasm). However, the risk of AML transformation 
significantly varies between MPNs.2 While transformation to AML is a rare event in ET (1-5% of 
patients), leukemic transformation occurs in 20-30% of MF patients (20-30%).2  
The process of leukemic transformation in MPN is not well understood. To identify somatic mutations 
that may contribute to the leukemic transformation process in MPNs investigations have focused on 
the identification of mutations in samples harvested before and after AML transformation using whole 
exome or targeted sequencing approaches. The comparison of the genetic profile of the two disease 
phases allows the identification of genetic aberrations that were acquired during the leukemic 
transformation process. However, to determine whether these genetic aberrations actively contribute 
to disease progression, their functional validation in vitro and in vivo is required.  
The spectrum of somatic mutations significantly varies between de novo AML and AML secondary to a 
MPN (post-MPN AML) suggesting a distinct pathogenic mechanism.16 The acquisition of somatic 
mutations in the tumor suppressor TP53 in MPNs is significantly associated with AML transformation 
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and correlates with reduced overall survival in retrospective studies.16 Accordingly, the expression of 
JAK2-V617F in mouse bone marrow TP53 knockout cells leads to the development of AML in mice 
and demonstrates that TP53 mutations functionally contribute to the leukemic transformation process 
in JAK2 mutant MPN.17 In addition to mutations in TP53, amplification of chromosome 1q containing 
the gene encoding for MDM4 has been associated with AML transformation. MDM4 is a known 
inhibitor of TP53 and upregulation of MDM4 in AML secondary to MPN is mutually exclusive to TP53 
mutations. Together mutations in TP53 and gain of chromosome 1q are found in almost 50% of post-
MPN AML making the TP53 axis, the most frequently affected genetic pathway.18 
Other somatic mutations that are associated with increased risk of leukemic transformation and 
potentially contribute to the progression to post-MPN AML include mutations in the epigenetic 
regulators DNMT3a, ASXL1, EZH2, TET2 and the B-cell transcription factor IKZF1.19 While the 
evidence for the involvement of TP53 in transformation to MPN blast phase is solid (see above) the 
functional contribution of these other somatic mutations remains to be determined.  
 
 
The contribution of CALR mutations to the pathogenesis of MPN  
In contrast to JAK2, more than 50 mutations have been described in CALR, which all lead to a mutant-
specific reading frame.1,10 CALR type 1 (52 base pair (bp) deletion) and CALR type 2 (5 bp insertion) 
are the two most frequently detected CALR mutations and cover >80% of the mutational spectrum of 
CALR. CALR mutations affect the C-terminal, which contains a lysine, aspartic acid, glutamic acid, 
leucine (KDEL) motif and a Ca2+-binding domain (Figure 1). 
 
 
The discovery of CALR mutations in ET and MF patients is particularly intriguing since CALR 
mutations have not been described in other cancers. Furthermore, unlike JAK2 and ABL, CALR is not 
kinase, a tumor suppressor or a known oncogene. CALR is a molecular chaperone for N-glycoproteins 
(GPs), modulates calcium homeostasis and acts as a prophagocytic signal on the cell surface.  
Moreover, CALR is essential for cardiac development and homozygous CALR knockout embryos die 
before day 14.5 due to a severe defect in early cardiogenesis.20 
Figure 1. Functional CALR domains and most frequent CALR mutations (adapted from Nangalia et al.).1 The CALR 
protein is composed of a N-terminal, a Proline-rich and a C-terminal domain, which contains a KDEL motif. The two most 
frequent CALR mutations are shown below. Both, type 1 (L367fs*46, 52 bp deletion) and type 2 (K385fs*47, 5 bp insertion), 
lead to a novel common peptide sequence, which lacks the KDEL motif.   
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The unique association of CALR mutations with ET and MF suggests an association between CALR 
mutations and megakaryocyte development since both disorders are characterized by pathologic 
proliferation and/or differentiation of the megakaryocytic lineage.2 Of note, the CALR type 1 mutation is 
predominantly associated with MF, while the type 2 mutation is more prevalent in ET suggesting 
functional differences between the two mutants.21  
MPN patients with CALR mutations respond equally well to JAK-inhibitor therapy as patients with 
JAK2 mutations, which supports the involvement of the JAK-STAT pathway in the pathogenesis of 
CALR mutated MPNs.11,22 In line with these observations, recent studies demonstrate that the mutated 
CALR protein, but not the wild-type protein, binds and leads to pathological activation of the 
thrombopoietin receptor (MPL) thereby inducing JAK-STAT signaling.3,21,23  
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2. Results 
 
Theocharides A, Boissinot M, Girodon F, Garand R, Teo S-S, Lippert E, Tichelli A, 
Hermouet  S, Skoda RC. 
Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently 
negative for the JAK2-V617F mutation 
Blood. 2007 Jul 1;110(1):375-9. Epub 2007 Mar 15.  
 
At the time of the first study presented in the Habilitationsschrift the relevance of the JAK2-V617F 
mutation in transformation from MPN to AML was unclear. To study the role of the JAK2-V617F 
mutation in leukemic transformation, we examined 27 patients with MPNs who transformed to AML.13 
DNA was isolated from MPN samples at MPN diagnosis and from samples after transformation to 
AML. At MPN diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 
patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-
negative AML. Acquired loss of heterozygosity (LOH), which arises through mitotic recombination, is a 
frequent genetic phenomenon in hematopoietic cancers.24 We hypothesized that JAK2-V617F-
negative AML may arise from a HSC which has lost the JAK2-V617F mutation through LOH, followed 
by the expansion of the AML clone with both JAK2 wild-type alleles. However, microsatellite analysis 
in a female patient in our study showed that LOH was not responsible for the transition from JAK2-
V617F-positive MPN to JAK2-V617F-negative AML, and clonality determined by the MPP1 
polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental 
X chromosome. This was independently confirmed by another study and excluded LOH as possible 
mechanism for transformation to JAK2-V617F-negative AML.25  
We then assessed whether samples at MPN and at AML diagnosis carried common cytogenetic 
aberrations. Detection of genetic aberrations at both stages of the disease suggests that both, MPN 
and AML, have a common clonal ancestor. In one patient positive for JAK2-V617F in neutrophil 
granulocytes at AML transformation, but with JAK2-V617F-negative leukemic blasts (i.e. very 
immature leukemic cells), we found a deletion of chromosome 11q in neutrophils and the leukemic 
blasts. This observation suggests that both, the JAK2-V617F positive granulocytes and the JAK2-
V617F leukemic blasts have a common clonal ancestor. In that case the JAK2-V617F mutation may 
have been chronologically acquired in a hematopoietic stem or progenitor cell after the acquisition of 
the deletion in chromosome 11q. Presumably the HSC, which carries the deletion of chromosome 11q, 
but not the JAK2-V617F mutation acquired other somatic mutations that led to AML transformation. 
From our study we concluded that JAK2-V617F-positive MPN frequently yield JAK2-V617F-negative 
AML, and that AML transformation of a common JAK2-V617F-negative ancestor represents a possible 
mechanism.  
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Theocharides A, Dobson S, Laurenti E, Notta F, Voisin V, Cheng P, Yuan J, Guidos CJ, Minden M, 
Mullighan C, Torlakovic E, Dick JE. 
Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in 
xenografts. 
Leukemia. 2015 Jan;29(1):177-87. Epub 2014 May 5. 
 
Historically, our understanding of mechanisms underlying human leukemogenesis are inferred from 
genetically engineered mouse models. Relatively, few models that use primary human cells 
recapitulate the full leukemic transformation as assayed in xenografts.26-28 In the second project 
presented in the Habilitationsschrift we aimed at developing a model for BCR-ABL1 positive B 
lymphoblastic leukemia (B-ALL).29 In BCR-ABL1 positive B-ALL mutations in the B-cell transcription 
factor IKAROS (encoded by IKZF1) are detected in >80% of patients and lead to the formation of a 
dominant negative isoform (Ik6), which suppresses the function of wild-type IKAROS.30,31 
We expressed BCR-ABL1 and Ik6 simultaneously in human cord blood cells enriched for 
hematopoietic stem and progenitors. In contrast to our prediction mice did not develop B-ALL, but 
developed aggressive AML with disseminated myeloid sarcomas (i.e. solid tumors composed of 
leukemic cells) within 4 weeks following transplantation of cord blood transduced with vectors 
expressing BCR-ABL1 and Ik6. BCR-ABL-Ik6 cells also showed a competitive advantage in vitro. We 
performed gene expression profiling and compared cord blood cells transduced with Ik6, BCR-ABL1 
and both BCR-ABL1 and Ik6. Our data shows that Ik6 induces transcriptional programs in BCR-ABL1-
transduced progenitors that contained repressed B-cell progenitor programs, along with strong 
stemness, proliferation and granulocyte-monocytic progenitor (GMP) signatures, a novel combination 
not induced in control groups. Interestingly, our model also uncovered an active interleukin 6 (IL-6) 
pathway in cells expressing BCR-ABL1 and Ik6 pointing towards a central role of IL-6 in AML 
transformation, which parallels findings that come from clinical observations predicting a functional role 
for IL-6 in AML.  
From our study we concluded that wild-type IKAROS restrains stemness properties and has tumor 
suppressor activity in BCR-ABL1-initiated leukemia. Interestingly, although IKAROS 
mutations/deletions are common in lymphoid transformation, they are found also at low frequency in 
AML that progress from a prior MPN state.32 Our experimental system therefore provides an excellent 
functional model to gain insight into these cases of AML transformation. IKAROS loss of function may 
act as a secondary mutation in the transformation of MPN to AML as discussed in the first project 
described above. More generally, the data points to the importance of deregulated stemness/lineage 
commitment programs in human myeloid leukemogenesis.  
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Theocharides A, Lundberg P, Lakkaraju A, Lysenko V, Myburgh V, Aguzzi A, Skoda R, Manz M 
Homozygous Calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase 
deficiency 
Blood. 2016 Jun 23;127(25):3253-9. Epub 2016 Mar 24. 
 
The pathogenesis of acquired myeloperoxidase (MPO) deficiency, a rare phenomenon observed in 
patients with Philadelphia chromosome-negative MPNs, is unknown.33 MPO is a lysosomal heme GP 
expressed exclusively in myeloid cells that is folded by CALR in the ER.34,35 It catalyzes the 
conversion from hydrogen peroxide to hypochlorous acid and is essential for optimal oxygen-
dependent anti-microbial activity.34,35 Whether CALR mutations affect the chaperone function of CALR 
remains to be determined.  
In the third study presented in the Habilitationsschrift we hypothesized that acquired MPO deficiency in 
MPN could be associated with the presence of CALR mutations.15 A cohort of 317 MPN patients (142 
PV, 94 ET and 81 MF) was screened for MPO deficiency using an automated ADVIA blood cell 
counter. The ADVIA cell counter uses MPO activity to generate a differential white blood cell count 
and neutrophil granulocytes are identified by their high expression of MPO.36 As a consequence 
patients with MPO deficiency lack neutrophil granulocytes in the automated, but not in the manual cell 
count performed by light microscopy.  
In our cohort MPO deficiency was observed in 6/81 MF patients (7.4%), but not in PV or ET patients. 
Since MPO is essential for anti-microbial activity we assessed the history of infections in MPO 
deficient patients. Susceptibility to infections had been documented in 2/6 (33%) MPO deficient 
patients. Five out of six patients with MPO deficiency carried a homozygous CALR mutation and were 
also deficient in eosinophilic peroxidase (EPX), another GP folded by CALR in the ER. In contrast, one 
MF patient with a JAK2-V617F mutation and MPO deficiency carried two previously reported MPO 
mutations in inherited MPO deficiency and showed normal EPX activity.37 Patients with homozygous 
CALR mutations had reduced MPO protein, but normal MPO mRNA levels supporting a post-
transcriptional defect in MPO production. This data suggests that patients with homozygous CALR 
mutations develop a defect in the chaperone function of CALR that leads to MPO and EPX deficiency. 
In contrast, MPO deficiency in the patient with a JAK2 mutation is the consequence of an inherited 
MPO gene mutation and is coincidental with the MPN.  
To determine whether the absence functional CALR in the presence of homozygous CALR mutations 
leads to MPO deficiency we expressed human MPO in CALR knockout mouse embryonic fibroblasts. 
These experiments showed that in the absence of CALR immature MPO protein precursors are 
produced, but then degraded in the proteasome. Therefore acquired MPO deficiency in MPN is the 
consequence of degradation of immature, presumably misfolded MPO precursors and in contrast to 
inherited MPN deficiency is not due to a transcriptional defect.  
In summary, four decades after the first description of acquired MPO deficiency in MPN our study 
provides the molecular correlate associated with this phenomenon and evidence that CALR mutations 
can affect the biosynthesis of GPs. 
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3. Discussion 
 
The origin of post-MPN AML 
In 2007, others and us demonstrated that AML in JAK2 mutated MPN can originate from a 
hematopoietic stem or progenitor cell that does not carry the JAK2 mutation.13,25 In our work we 
described 9 patients with JAK2 mutated MPN who transformed to JAK2 unmutated AML. In one 
patient we found a common cytogenetic aberration in the MPN and the AML phase suggesting a 
common clonal origin. In line with the hematopoietic hierarchy we proposed three mechanisms 
compatible with the “loss” of the JAK2 mutation in the transformation to AML (Figure 2).  
 
In the first model the acquisition of the JAK2 mutation is a late genetic event and AML originates from 
an HSC that does not carry a JAK2 mutation yet. The second model predicts that AML originates from 
an MPN-independent JAK2 unmutated HSC clone that does not carry common genetic aberrations. 
Finally, JAK2 unmuated AML could arise through mitotic recombination/LOH that leads to uniparental 
disomy of the JAK2 wild-type allele, a hypothesis that we rejected by microsatellite analysis of a 
female patient.13,25 
In the first model mutation(s) in HSCs chronologically precede the JAK2 mutation. Recent studies 
have investigated the order of acquisition of somatic mutations in MPN. JAK2 mutations and mutations 
in the epigenetic regulator Tet methylcytosine dioxygenase 2 (TET2) frequently co-occur in MPNs.38 
MPN patients with concomitant JAK2 and TET2 mutations can be categorized into “JAK2-first” and 
“TET2-first” subgroups depending on the chronological order of acquisition.39 Although our study did 
Figure 2. Hypothetical model for the transformation into JAK2 unmutated AML proposed in 2007. Model 1: AML 
originates from a hematopoietic stem or progenitor cell that does not carry the JAK2 mutation. Model 2: JAK2 unmutated 
AML originates from a HSC that is independent of the JAK2 mutated clone that gave rive to the MPN. Model 3: JAK2 
unmutated post-MPN AML originates from a JAK2 unmutated hematopoietic stem and progenitor cell in which the JAK2 
mutation was “lost” through mitotic recombination.  
mitotic 
recombination 
heterozygous 
JAK2-V617F 
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not assess TET2 mutations in the samples investigated the “TET2-first” model is compatible with the 
first model. In this model AML could arise from a TET2 mutated, but JAK2 unmutated HSC. However 
in the discussed study the number of MPN patients with transformation to AML was not indicated, 
most likely due to the low number of patients.40 In the study by Lundberg et al. the chronological 
acquisition of somatic mutations was assessed in 12 patients with TET2 mutations.38 In contrast to the 
study by Ortmann et al. (see above) all but one of these patients carried the TET2 mutation already at 
MPN diagnosis and mutations in TET2 occurred mostly before the JAK2 mutation. Moreover the 
presence of a TET2 mutation correlated with reduced overall survival and increased risk of leukemic 
transformation. No consistent pattern regarding the order of acquisition was observed for mutations in 
other epigenetic modifiers such as EZH2 and ASXL1. In accordance with our first model outlined 
above this model is compatible with a leukemic clone that arises from a JAK2 unmutated ancestral 
clone and leads to JAK2 unmutated AML (Figure 2).  
In the second model AML arises de novo from an “MPN independent” JAK2 unmutated HSC. Biclonal 
disease in post-MPN AML may be identified by the absence of JAK2-V617F and a mutational pattern 
that resembles de novo AML. The mutational pattern of de novo AML significantly differs from AML 
secondary to an antecedent MPN. While mutations in FLT3-ITD, NPM1 and NRAS are more 
frequently found in the de novo AML, mutations in TP53, RUNX1 and CBL are often acquired during 
MPN transformation to AML and not present at MPN diagnosis.16  
The identification of somatic genetic aberrations that are acquired during leukemic transformation 
suggests their involvement in post-MPN AML pathogenesis. However, for most of them, their 
functional contribution remains to be determined. The work by Rampal et al. elegantly shows that the 
loss of TP53 function in the presence of the JAK2-V617F mutation models post-MPN AML.17 The 
second study presented in the Habilitationsschrift investigates the functional collaboration between 
BCR-ABL1 and Ik6, a dominant-negative isoform of IKAROS, in leukemic transformation.14 In contrast 
to our first hypothesis (see results section) immune-compromised mice transplanted with double-
transduced cord blood cells developed AML, but not B-ALL. The model described in our study 
resembles AML secondary to antecedent CML. In line with our observation, mutations in IKAROS 
have been described in post-CML AML and AML secondary to MPNs in up to 20% of cases.32,41 
These observations suggest that the loss of IKAROS function may contribute to the pathogenesis of 
post-MPN AML in a subgroup of MPN patients. Importantly, IKAROS mutations have not been 
described in the chronic phase of CML and MPNs. This suggests that IKAROS mutations functionally 
promote leukemic transformation. Interestingly, our study uncovered an active role of IL-6 in AML 
transformation and may provide a rational for anti-IL-6 therapy in post-CML and post-MPN AML. Anti-
IL-6 therapy is approved for the treatment of multicentric Castleman’s disease and the efficacy of anti-
IL-6 therapy has been assessed in patients with multiple myeloma.42 Pharmacokinetic and biosafety 
studies have been performed and will facilitate translation of promising experimental data into clinical 
trials for other disease such as post-CML/MPN AML. 
 
Disturbed chaperone function in CALR mutated MPN 
In the third study presented in the Habilitationsschrift we demonstrate that homozygous CALR 
mutations lead to MPO and eosinophilic peroxidase (EPX) deficiency in patients with MF.15 MPO and 
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EPX are two GPs known to be chaperoned by CALR and our data represents the first evidence that 
CALR mutations can affect the chaperone function of CALR. 
I hypothesize that CALR mutations affects the chaperone function of CALR through distinct 
mechanisms (Figure 3).  
 
 
 
 
 
 
Reduced availability of CALR in the ER could influence its chaperone capacity and affect the 
maturation of GPs. CALR mutations affect the C-terminal domain and lead to loss of the KDEL 
sequence.1,10 The KDEL motif is important for the retention and the retrieval of CALR in and to the ER. 
However, whether the loss of the KDEL motif in the presence of CALR mutations leads to the 
mislocalisation of CALR in subcellular organelles remains unclear. While the study by Klampfl. et al did 
not find a difference in localization compared to wild-type CALR, the study by Nangalia et al. 
suggested that CALR mutants are not constrained to the ER.1,10 Mislocalisation of CALR in the 
presence of CALR mutations was later described in the work by Chachoua et al. who isolated 
postnuclear fractions by sucrose density gradients.21 In these experiments the wild-type, but not the 
mutant CALR protein equilibrated with the ER-marker GRP78 supporting a misclocalization of the 
mutant. This was further confirmed by high-resolution confocal microscopy, which demonstrated that 
the wild-type, but not the mutant CALR protein colocalize with the ER resident protein Calnexin, while 
the mutant protein colocalized with ERGIC53, a protein resident in the ER to Golgi intermediate 
compartment. In summary, the data is more supportive of an altered subcellular localization of mutated 
CALR proteins, which may impact on the chaperone capacity.  
An alternative hypothesis suggests that the binding of GPs to CALR is altered in the presence of 
CALR mutants consecutively leading to GP misfolding (Figure 3). GPs bind to the N-terminal domain 
of CALR, which is unaffected by CALR mutations.  However, a recent observation suggests that the 
interaction of CALR mutants with MPL, another GP, is abnormal (Figure 4).3 The binding of MPL to 
wild-type CALR is inhibited by the P-domain of CALR. In contrast to the wild-type, the mutant C-
terminal inhibits the inhibitory function of the P-domain and consecutively allows MPL to bind to CALR. 
This pathologic interaction leads to activation of JAK-STAT signaling downstream of MPL. It is 
conceivable that the binding to CALR of other GPs like MPO and EPX is affected in the presence of 
CALR mutations and leads to a maturation defect and consecutive degradation of CALR substrates. 
This is further supported by the study by Chachoua et al., which shows that the maturation of MPL is 
altered in the presence of CALR mutants and by earlier studies, which demonstrate a maturation 
defect of MHC class I and Tapasin, two GPs chaperoned by CALR, in CALR knockout cells.21,43 
 
 
 
Figure 3. Possible consequences of CALR 
mutations on the interactions of CALR with 
GP. Alterations in the C-terminal domain of 
CALR may lead to a reduced retention of CALR 
in the ER (blue arrow) and consecutively 
decreased availability of CALR to fold GP.  
Alternatively, CALR mutations may affect the 
direct interaction with GPs (red blizzard). 
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Although the deficiencies in MPO and EPX likely do not directly contribute to the pathogenesis of 
CALR mutated MPN the maturation of GPs that control cell proliferation and differentiation, such as 
tumor suppressors, epigenetic regulators and cell cycle checkpoints may be affected in the presence 
of CALR mutants. In particular, the loss of proteins involved in the negative regulation of JAK2 
including LNK, SOCS family members and CBL may contribute to MPN development. Loss of function 
mutations have been reported in the E3 ubiquitin ligase CBL in a wide range of myeloid malignancies. 
44 CBL targets specific proteins for proteasomal degradation and acts as a negative regulator of 
cytokine receptor signaling.  
In addition to pathological activation of JAK-STAT signaling, the direct or indirect activation of 
alternative kinases may contribute to the pathogenesis of MPN. A recent study shows that Zfand2b 
(encodes the highly conserved ER resident protein AIRAPL) knockout mice develop a 
myeloproliferative disease characterized by the activation of Insulin-like Growth Factor 1 Receptor 
(IGF1R) signaling and treatment with the IGF1R inhibitor NVP-AEW541 reverts disease.45 Although 
activation of JAK-STAT signaling is not observed in these mice, MPN patients with JAK2 or CALR 
mutations show downregulation of ZFAND2B and upregulation of IGF1R signaling probably as a 
consequence of microRNA 125a-3p upregulation. This data shows that dysregulated proteostasis 
presumably induced by JAK2 or CALR mutations contributes to MPN development by activation of 
alternative pathways involved in cell proliferation and differentiation. Future unbiased approaches 
comparing the proteome and the glycoproteome of wild-type and mutant CALR will help identifying 
candidate proteins and lead to the identification of novel potential therapeutic targets in MPN.  
 
Susceptibility to infections in MPN patients with acquired MPO deficiency 
MPO deficiency can either be inherited or acquired. It remains to be determined whether functional 
differences between inherited and acquired MPO deficiency exist and whether acquired MPO 
deficiency leads to increased susceptibility to recurrent and opportunistic infections in patients with an 
underlying causative disorder such as MPN. In the third study presented in the Habilitationsschrift 2/6 
MPN patients (33%) with acquired MPO deficiency suffered from severe recurrent infections.15 In a 
large study partial MPO deficiency was detected in approximately 0.2% of healthy individuals, 
whereas complete MPO deficiency was found only in 55/150’000 (0.04%) study subjects.33 In the 
same study, an increased incidence of serious infections and inflammatory disease was reported in 
patients with complete MPO deficiency.33 All patients with homozygous CALR mutations in our study 
presented with complete MPO deficiency. The incidence of MPO deficiency reported in our study is 
therefore significantly higher than the one reported in subjects with the inherited form. Moreover, 
although the number of patients is too small to draw solid conclusions the susceptibility to infections 
Figure 4. Mechanism of CALR-MPL interaction in the presence of CALR mutants (adapted from Araki et al.).3 The P-
domain of CALR inhibits the binding of MPL to the N-terminal domain (left). In the presence of CALR mutations the novel C-
terminal domain of CALR inhibits the function of the P-domain and allows binding of MPL to CALR (right).  
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seems higher in acquired than in inherited MPO deficiency. An increased susceptibility to infectious 
complications in patients with myeloid disease may be simply related to the underlying hematological 
neoplasms and immunosuppressive therapy. However, an observation made more than 50 years ago 
by Klebanoff et al. could point towards functional differences between inherited and acquired MPO 
deficiency.46 Subjects with inherited MPO deficiency may have adapted to the defect in hydrogen 
peroxide to hypochloric acid conversion and developed alternative molecular anti-microbial 
strategies.47 These mechanisms may not be in place in subjects who develop MPO deficiency during 
their lifetime, leading to increased susceptibility to infections and accumulation of reactive oxygen 
species.  
The identification of MPN patients at risk for infectious complications may be of particular importance 
for patients treated with JAK-inhibitors, which increase the risk of infections with varicella zoster and 
other opportunistic pathogens.11,22 
 
In summary, the research findings discussed in the Habilitationsschrift have contributed to a better 
understanding of the pathogenesis of MPN. The knowledge about molecular events that contribute to 
leukemic transformation may allow the development of therapeutic strategies that act at an early 
disease stage and prevent progression to AML. Chaperone malfunction constitutes a novel 
mechanism in the development of hematopoietic cancer and the findings described will open up new 
avenues of research in related disorders like myelodysplastic syndromes and AML. Therefore the 
significance of the data lies not only in MPN, but may be extended to a broad range of related myeloid 
neoplasms.  
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